Anika Therapeutics, Inc. (ANIK)

Anika Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	119.91	120.79	113.83	147.79	130.46
Revenue Growth (YoY)	-0.73%	6.12%	-22.98%	13.29%	13.83%
Cost of Revenue	43.3	37.51	40.61	58.39	61.43
Gross Profit	76.6	83.28	73.22	89.41	69.03
Selling, General & Admin	55.56	59.93	51.23	74.1	56.74
Research & Development	25.54	21.76	18.32	27.33	22.02
Operating Expenses	81.1	81.69	69.55	101.42	78.76
Operating Income	-4.5	1.59	3.67	-12.02	-9.73
Interest Expense	-	-	-	-0.19	-0.3
Interest & Investment Income	2.34	2.31	0.65	-	-
EBT Excluding Unusual Items	-2.16	3.9	4.32	-12.2	-10.03
Merger & Restructuring Charges	-0.61	-0.75	-	-6.47	-4.1
Impairment of Goodwill	-	-	-	-	-42.52
Asset Writedown	-	-	-	-	-2.44
Other Unusual Items	-	-	-	21.1	30.47
Pretax Income	-2.76	3.16	4.32	2.43	-28.62
Income Tax Expense	6.06	6.6	2.12	-1.71	-4.64
Earnings From Continuing Operations	-8.83	-3.44	2.2	4.13	-23.98
Earnings From Discontinued Operations	-47.56	-79.23	-17.06	-	-
Net Income	-56.39	-82.67	-14.86	4.13	-23.98
Net Income to Common	-56.39	-82.67	-14.86	4.13	-23.98
Shares Outstanding (Basic)	15	15	15	14	14
Shares Outstanding (Diluted)	15	15	15	15	14
Shares Change (YoY)	0.44%	0.65%	-0.50%	2.90%	-1.06%
EPS (Basic)	-3.83	-5.64	-1.02	0.29	-1.69
EPS (Diluted)	-3.83	-5.64	-1.02	0.28	-1.69
Free Cash Flow	-2.33	-7.22	-3.08	3.25	11.44
Free Cash Flow Per Share	-0.16	-0.49	-0.21	0.22	0.80
Gross Margin	63.89%	68.95%	64.33%	60.49%	52.91%
Operating Margin	-3.75%	1.32%	3.22%	-8.13%	-7.46%
Profit Margin	-47.02%	-68.44%	-13.05%	2.80%	-18.38%
Free Cash Flow Margin	-1.94%	-5.97%	-2.70%	2.20%	8.77%
EBITDA	3.63	15.81	18.16	2.3	3.74
EBITDA Margin	3.02%	13.09%	15.95%	1.56%	2.86%
D&A For EBITDA	8.12	14.22	14.49	14.32	13.46
EBIT	-4.5	1.59	3.67	-12.02	-9.73
EBIT Margin	-3.75%	1.32%	3.22%	-8.13%	-7.46%
Effective Tax Rate	-	208.97%	49.12%	-	-

Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q